Latest stories on GSK
GSK beat Q3 2026 earnings estimates as specialty medicine sales grew
Quartz64 · neutralearnings
GSK (GSK) Reports Strong Q3 Sales and Advances Specialty Drug Pipeline
GuruFocus71 · bullishearnings
GSK Projects Revenue and Profit Growth Through 2026 Amid Dividend Sustainability Concerns (GSK)
GuruFocus58 · neutralearnings
GSK backs 2026 guidance, sees core EPS growth 7%-9%
The Fly63 · neutralearnings
GSK reports Q3 core EPS 54.6p, up 1% at CER
The Fly56 · neutralearnings
GSK Reports 4% Revenue Growth in Q3, Stock Performance Insights
GuruFocus58 · neutralearnings
GSK (GSK) Declares 17.00p Q3 2026 Dividend, Signaling Solid Payout Sustainability
GuruFocus58 · neutralgeneral
GSK declares $0.4524/ADS or 17p/share dividend
Seeking Alpha56 · neutralgeneral
Why is GSK stock sliding today?
Investing.com Markets38 · neutralgeneral
GSK Reports Q3 2026 Results, Reinforces Dividend Sustainability Amid Modest Overvaluation (Ticker: GSK)
GuruFocus58 · neutralearnings
GSK (GSK) Q3 Earnings Beat Expectations, Reinforcing Dividend Appeal Amid Specialty Medicines Growth
GuruFocus67 · bullishearnings
GSK Sales Get Boost From Specialty Medicines
Morningstar63 · neutralearnings
GSK delivers Q3 earnings beat, reaffirms 2026 outlook
Seeking Alpha64 · neutralearnings
GSK Non-GAAP EPS of £0.55 beats by £0.04, revenue of £8.89B beats by £50M; reaffirms FY outlook
Seeking Alpha67 · bullishearnings
GSK Earnings: GSK Slumps After Quarterly Report Shows Vaccine Sales Falling
Bloomberg34 · bearishearnings
GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
Seeking Alpha56 · neutralproduct/pr
GSK (GSK) Prepares to Report Q3 Earnings Amid Dividend Sustainability Focus
GuruFocus52 · neutralearnings
GSK’s return to cancer starting to pay off, STAT reports
The Fly63 · neutralproduct/pr
GSK is expecting its cancer drug clinical pipeline to nearly double in 2027
Quartz64 · neutralproduct/pr
GSK to nearly double cancer drug trials in 2027 as deals boost pipeline - report
Investing.com Markets64 · neutralproduct/pr
GSK to nearly double cancer drugs in late-stage trials next year: WSJ
Seeking Alpha64 · neutralproduct/pr
GSK Accelerates Cancer Drug Development Amid Strategic Acquisitions
GuruFocus64 · neutralproduct/pr
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
WSJ74 · bullishproduct/pr
GSK Highlights Strong Phase III Osteosarcoma Data for Ris-Rez from China Trial
TipRanks64 · neutralproduct/pr
GSK Reports October Executive Notional ADS Acquisition on NYSE
TipRanks50 · neutralgeneral